Wella
This article was originally published in The Rose Sheet
Executive Summary
German company's management board agrees to hold extraordinary general meeting following minority shareholder group's recent request for an opportunity to air grievances related to company's acquisition by Procter & Gamble, Wella announces. Slated for Feb. 3, meeting will allow shareholders to discuss proposed steps to protect minority interests, including a special audit to investigate alleged breaches of fiduciary duty by Wella management during and after the P&G tender offer. Minority group outlined issues and proposed solutions in a Nov. 10 letter to Wella CEO Heiner Gurtler (1"The Rose Sheet" Nov. 17, 2003, p. 8). While agreeing to the meeting, Wella asserted there is "no reason" for the shareholder proposal and that the criticism of Wella's management board is "unjustified and inappropriate"...
You may also be interested in...
Wella Minority Shareholders Call For Investigation
A group of Wella minority shareholders are calling for an "extraordinary general meeting" with the firm's management board to discuss three resolutions aimed at protecting their interests following the company's acquisition by Procter & Gamble
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.